Figure 2

In vivo efficacy of OlPC-liposomes against L. major CL.

Female Balb/c mice received 10 × 10⁶ stationary phase L. major promastigotes transfected with luciferase at the tail base. After 12 weeks, mice were treated 2 × 5 days with PBS vehicle or OlPC-liposomes: 36–90 μg/day administered with a tattoo device (tattoo), 30 mg/kg/day IP, or 900 μg/day as a topical drop on the top of the lesion (topic). Lesions were measured from the start day of the treatment (Day 0) on individual pictures taken on Day 0, 7, 14, 21 and 28 for each mouse. Lesion areas were calculated using the Adobe Photoshop® software. Representative pictures of lesions from each group are shown in (a); mean lesion sizes (±SEM) up to Day 28 are presented in (b); P < 0.05 between treated (*tattoo), (⁺IP) and vehicle groups (n = 7–9). Individual lesion sizes per group on Day 28 are shown in (c).